Process for the manufacture and use of pancreatin micropellet cores
A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portion of the intestine of a mammal for release.
1. A process for the manufacture of enteric-coated pancreatin micropellets, comprising the steps of:
a. preparing an extrudable mixture consisting of:
i. pancreatin;
ii. at least one pharmaceutically acceptable binding agent, wherein the binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000; and
iii. one or more enzyme-friendly organic solvents in an amount sufficient to form an extrudable mixture;
b. creating pancreatin micropellet cores from the extrudable mixture by extrusion;
c. forming the uncoated pancreatin micropellet cores into approximately spherical or approximately ellipsoidal shape, wherein step (c) consists of rounding, in a spheronizer, the uncoated pancreatin micropellet cores in the presence of additional enzyme-friendly organic solvent;
d. removing the one or more enzyme-friendly organic solvents from the pancreatin micropellet cores such that the pancreatin micropellet cores are substantially free of the one or more enzyme-friendly organic solvents; and
e. coating the pancreatin micropellet cores with an enteric coating;
wherein the pancreatin micropellet cores are substantially free of synthetic oils in each of steps (b), (c), and (d).
2. The process of claim 1 wherein the pharmaceutically acceptable binding agent is polyethylene glycol 4000.
3. The process of claim 2 wherein the pancreatin is present between 70% and 90% weight to weight of the uncoated pancreatin micropellet cores.
4. The process of claim 2 wherein polyethylene glycol 4000 is present between 10% and 30% weight to weight of the uncoated pancreatin micropellet cores.
5. The process of claim 1 wherein the one or more enzyme-friendly organic solvents is selected from the group consisting of: acetone, chloroform, dichloromethane, methanol, ethanol, 1-propanol, 2-propanol, 2-butanol, tert-butanol and mixtures of said solvents.
6. The process of claim 1 wherein the pancreatin is present at 80% weight to weight of the uncoated pancreatin micropellet cores.
7. A pharmaceutical composition comprising an enteric-coated pancreatin micropellet manufactured according to the process of claim 1 .
8. The pharmaceutical composition of claim 7 , wherein the enteric-coated pancreatin micropellet comprises:
(a) a pancreatin micropellet core, wherein the core consists of:
(i) 70% to 90% pancreatin; and
(ii) 10% to 30% of the pharmaceutically acceptable binding agent; and
(b) the enteric coating;
wherein the percentages of components in the pancreatin micropellet core are weight to weight of the uncoated pancreatin micropellet core.
9. The pharmaceutical composition of claim 7 , wherein the enteric-coated micropellet is substantially free of synthetic oils.
10. The pharmaceutical composition of claim 8 , wherein at least of 55% of lipase activity in the composition is released within 30 minutes in a buffer solution at pH 6 as measured according to United States Pharmacopoeia.
11. A delayed-release oral pharmaceutical composition comprising:
(a) a pancreatin core, wherein the core consists of:
(i) 65% to 90% pancreatin;
(ii) 5% to 30% of at least one pharmaceutically acceptable binding agent;
(iii) optionally, at least one pharmaceutically acceptable excipient, wherein synthetic oils are not pharmaceutically acceptable excipients; and
(iv) an enzyme-friendly organic solvent, wherein synthetic oils are not enzyme-friendly organic solvents, wherein the percentages of components are weight to weight of the core; and
(b) an enteric coating on the core;
wherein at least 55% of lipase activity in the composition is released within 30 minutes in a buffer solution at pH 6 as measured according to United States Pharmacopoeia.
12. The pharmaceutical composition of claim 11 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
13. The pharmaceutical composition of claim 11 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5.
14. The pharmaceutical composition of claim 11 , wherein the pancreatin cores are in the form of micropellets.
15. The pharmaceutical composition of claim 14 , wherein the micropellets have a diameter of about 0.5 mm to about 2.0 mm.
16. A delayed-release oral pharmaceutical composition comprising:
(a) pancreatin micropellet cores comprising
(i) pancreatin;
(ii) at least one pharmaceutically acceptable binding agent, wherein synthetic oils are not pharmaceutically acceptable binding agents; and
(iii) an enzyme-friendly organic solvent, wherein synthetic oils are not enzyme-friendly organic solvents; and
(b) an enteric coating on the cores;
wherein the enteric coating is substantially free of monomeric phthalic acid esters;
wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5; and
wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes in a phosphate buffer solution at pH 6.0 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
17. The pharmaceutical composition of claim 16 , wherein greater than 0% of lipase activity in the enteric coated pancreatin micropellets is released within 10 minutes in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
18. The pharmaceutical composition of claim 16 , wherein greater than 15% of lipase activity in the enteric coated pancreatin micropellets is released within 15 minutes, greater than 65% of lipase activity in the enteric coated pancreatin micropellets is released within 30 minutes, and greater than 75% of lipase activity in the composition enteric coated pancreatin micropellets is released within 45 minutes, in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
19. The pharmaceutical composition of claim 16 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
20. The pharmaceutical composition of claim 19 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
21. The pharmaceutical composition of claim 16 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core.
22. The pharmaceutical composition of claim 16 , wherein the pancreatin micropellet cores consist essentially of 10% to 30% of the at least one pharmaceutically acceptable binding agent by weight of the core.
23. The pharmaceutical composition of claim 22 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
24. The pharmaceutical composition of claim 23 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
25. The pharmaceutical composition of claim 16 , wherein the micropellet cores have a diameter of less than 5 mm.
26. The pharmaceutical composition of claim 16 , wherein the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
27. The pharmaceutical composition of claim 16 , wherein the enteric coating comprises hydroxypropyl cellulose, hydroxypropylmethyl acetate succinate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate or methyl cellulose.
28. The pharmaceutical composition of claim 16 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
29. The pharmaceutical composition of claim 26 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
30. The pharmaceutical composition of claim 16 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
31. The pharmaceutical composition of claim 28 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
32. The pharmaceutical composition of claim 16 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
33. The pharmaceutical composition of claim 28 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
34. The pharmaceutical composition of claim 16 , wherein the micropellet cores contain less than 3% water.
35. The pharmaceutical composition of claim 19 , wherein the micropellet cores contain less than 3% water.
36. The pharmaceutical composition of claim 21 , wherein the micropellet cores contain less than 3% water.
37. The pharmaceutical composition of claim 14 , wherein the micropellets have a diameter of less than 5 mm.
38. The pharmaceutical composition of claim 15 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
39. The pharmaceutical composition of claim 16 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core; the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000; and the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
40. The pharmaceutical composition of claim 16 , wherein the dissolution of the enteric coated pancreatin micropellets is determined according to United States Pharmacopoeia monograph for pancrelipase delayed-release capsules.
41. The pharmaceutical composition of claim 11 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
42. The pharmaceutical composition of claim 11 , wherein the enteric coating is substantially free of monomeric phthalic acid esters.
43. The pharmaceutical composition of claim 11 , wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes in a phosphate buffer solution at pH 6.0 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
44. The pharmaceutical composition of claim 11 , wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes when the dissolution of the enteric coated pancreatin micropellets is determined according to United States Pharmacopoeia monograph for pancrelipase delayed-release capsules.
45. A delayed-release oral pharmaceutical composition comprising:
(a) pancreatin micropellet cores comprising
(i) one active pharmaceutical ingredient consisting essentially of pancreatin,
(ii) at least one pharmaceutically acceptable binding agent, wherein synthetic oils are not pharmaceutically acceptable binding agents, and
(iii) an enzyme-friendly organic solvent, wherein synthetic oils are not enzyme-friendly organic solvents,
wherein the cores contain less than 2% synthetic oils; and
(b) an enteric coating on the cores, wherein the enteric coating is substantially free of monomeric phthalic acid esters;
wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5; and
wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes in a phosphate buffer solution at pH 6.0 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
46. The pharmaceutical composition of claim 45 , wherein greater than 0% of lipase activity in the enteric coated pancreatin micropellets is released within 10 minutes in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
47. The pharmaceutical composition of claim 45 , wherein greater than 15% of lipase activity in the enteric coated pancreatin micropellets is released within 15 minutes, greater than 65% of lipase activity in the enteric coated pancreatin micropellets is released within 30 minutes, and greater than 75% of lipase activity in the enteric coated pancreatin micropellets is released within 45 minutes, in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
48. The pharmaceutical composition of claim 45 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
49. The pharmaceutical composition of claim 48 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
50. The pharmaceutical composition of claim 45 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core.
51. The pharmaceutical composition of claim 45 , wherein the pancreatin micropellet cores consist essentially of 10% to 30% of the at least one pharmaceutically acceptable binding agent by weight of the core.
52. The pharmaceutical composition of claim 51 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
53. The pharmaceutical composition of claim 52 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
54. The pharmaceutical composition of claim 45 , wherein the micropellet cores have a diameter of less than 5 mm.
55. The pharmaceutical composition of claim 45 , wherein the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
56. The pharmaceutical composition of claim 45 , wherein the enteric coating comprises hydroxypropyl cellulose, hydroxypropylmethyl acetate succinate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate or methyl cellulose.
57. The pharmaceutical composition of claim 45 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
58. The pharmaceutical composition of claim 55 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
59. The pharmaceutical composition of claim 45 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
60. The pharmaceutical composition of claim 57 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
61. The pharmaceutical composition of claim 45 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
62. The pharmaceutical composition of claim 57 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
63. The pharmaceutical composition of claim 45 , wherein the micropellet cores contain less than 3% water.
64. The pharmaceutical composition of claim 48 , wherein the micropellet cores contain less than 3% water.
65. The pharmaceutical composition of claim 50 , wherein the micropellet cores contain less than 3% water.
66. The pharmaceutical composition of claim 45 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core; the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000; and the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
67. The pharmaceutical composition of claim 45 , wherein the dissolution of the enteric coated pancreatin micropellets is determined according to United States Pharmacopoeia monograph for pancrelipase delayed-release capsules.
68. A delayed-release oral pharmaceutical composition comprising:
(a) pancreatin micropellet cores consisting essentially of pancreatin and one or more suitable pharmaceutically acceptable excipients, wherein at least one excipient is a pharmaceutically acceptable binding agent, and an enzyme-friendly organic solvent, wherein synthetic oils are not pharmaceutically acceptable binding agents and wherein synthetic oils are not enzyme-friendly organic solvents; and
(b) an enteric coating on the cores, wherein the enteric coating is substantially free of monomeric phthalic acid esters;
wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5; and
wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes in a phosphate buffer solution at pH 6.0 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
69. The pharmaceutical composition of claim 68 , wherein greater than 0% of lipase activity in the enteric coated pancreatin micropellets is released within 10 minutes in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
70. The pharmaceutical composition of claim 68 , wherein greater than 15% of lipase activity in the enteric coated pancreatin micropellets is released within 15 minutes, greater than 65% of lipase activity in the enteric coated pancreatin micropellets is released within 30 minutes, and greater than 75% of lipase activity in the enteric coated pancreatin micropellets is released within 45 minutes, in a phosphate buffer solution at pH 6 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
71. The pharmaceutical composition of claim 68 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
72. The pharmaceutical composition of claim 71 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
73. The pharmaceutical composition of claim 68 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core.
74. The pharmaceutical composition of claim 68 , wherein the pancreatin micropellet cores consist essentially of 10% to 30% of the at least one pharmaceutically acceptable binding agent by weight of the core.
75. The pharmaceutical composition of claim 74 , wherein the at least one pharmaceutically acceptable binding agent is selected from the group consisting of: polyethylene glycol 2000, polyethylene glycol 3000, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 8000 and polyethylene glycol 10000.
76. The pharmaceutical composition of claim 75 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
77. The pharmaceutical composition of claim 68 , wherein the micropellet cores have a diameter of less than 5 mm.
78. The pharmaceutical composition of claim 68 , wherein the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
79. The pharmaceutical composition of claim 68 , wherein the enteric coating comprises hydroxypropyl cellulose, hydroxypropylmethyl acetate succinate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate or methyl cellulose.
80. The pharmaceutical composition of claim 68 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
81. The pharmaceutical composition of claim 78 , wherein the enteric coating comprises hydroxypropyl methyl cellulose acetate succinate or hydroxypropyl methylcellulose phthalate.
82. The pharmaceutical composition of claim 68 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
83. The pharmaceutical composition of claim 80 , wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in 0.1 mol/l hydrochloric acid at pH 1.
84. The pharmaceutical composition of claim 68 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
85. The pharmaceutical composition of claim 80 , wherein the composition has a relative gastric acid resistance of 90% or more following incubation for 2 hours in a phosphate buffer at pH 5.
86. The pharmaceutical composition of claim 68 , wherein the micropellet cores contain less than 3% water.
87. The pharmaceutical composition of claim 71 , wherein the micropellet cores contain less than 3% water.
88. The pharmaceutical composition of claim 73 , wherein the micropellet cores contain less than 3% water.
89. The pharmaceutical composition of claim 68 , wherein the pancreatin micropellet cores consist essentially of 70% to 90% pancreatin by weight of the core; the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000; and the micropellet cores have a diameter of about 0.5 mm to about 2.0 mm.
90. The pharmaceutical composition of claim 68 , wherein the dissolution of the enteric coated pancreatin micropellets is determined according to United States Pharmacopoeia monograph for pancrelipase delayed-release capsules.
91. A delayed-release oral pharmaceutical composition, the composition comprising:
(a) pancreatin micropellet cores consisting of
(i) pancreatin;
(ii) at least one pharmaceutically acceptable binding agent;
(iii) optionally, at least one pharmaceutically acceptable excipient, wherein synthetic oils are not pharmaceutically acceptable excipients; and
(iv) an enzyme-friendly organic solvent, wherein synthetic oils are not enzyme-friendly organic solvents; and
(b) an enteric coating on the cores, wherein the enteric coating is substantially free of monomeric phthalic acid esters;
wherein the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5; and
wherein at least 65% of lipase activity in the enteric coated pancreatin micropellets is released in 30 minutes in a phosphate buffer solution at pH 6.0 at 37° C., in a dissolution apparatus, using a paddle speed of 50 rpm, following 2 hours incubation in a gastric juice without enzymes at 37° C., in a dissolution apparatus, using a speed of 100 rpm.
92. The pharmaceutical composition of claim 91 , wherein the optional pharmaceutically acceptable excipient is selected from the group consisting of fillers and glidants.
93. The pharmaceutical composition of claim 92 , wherein the enteric coating comprises a plasticizer including cetyl alcohol and triethyl citrate.
94. The pharmaceutical composition of claim 91 , wherein the enzyme-friendly organic solvent is selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, 2-butanol, tert-butanol, and mixtures thereof.
95. A delayed-release oral pharmaceutical composition, the composition comprising:
(a) pancreatin micropellet cores comprising pancreatin, at least one pharmaceutically acceptable binding agent, and an enzyme-friendly organic solvent, wherein synthetic oils are not pharmaceutically acceptable binding agents and wherein synthetic oils are not enzyme-friendly organic solvents; and
(b) an enteric coating on the cores, wherein the enteric coating is substantially free of monomeric phthalic acid esters;
wherein the enteric coated micropellets have a diameter from about 0.7 mm to about 1.6 mm;
wherein, after storage for 5 months under slightly aggravated storage conditions, the composition has a relative gastric acid resistance of 75% or more following incubation for 2 hours in a phosphate buffer solution at pH 5, wherein slightly aggravated storage conditions comprise storing the enteric coated micropellets in hard gelatin capsules at 30° C. and 65% relative humidity.
96. The pharmaceutical composition of claim 95 , wherein the enteric coating comprises a plasticizer including cetyl alcohol and triethyl citrate.
97. The pharmaceutical composition of claim 95 , wherein the enzyme-friendly organic solvent is selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, 2-butanol, tert-butanol, and mixtures thereof.
98. The pharmaceutical composition of claim 45 , wherein the pancreatin micropellet cores comprise
(i) 70% to 90% pancreatin by weight of the core,
(ii) 10% to 30% of the at least one pharmaceutically acceptable binding agent by weight of the core, and
(iii) up to 5% of the enzyme-friendly organic solvent by weight of the core.
99. The pharmaceutical composition of claim 98 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.
100. The pharmaceutical composition of claim 91 , wherein the pancreatin micropellet cores comprise
(i) 70% to 90% pancreatin by weight of the core,
(ii) 10% to 30% of the at least one pharmaceutically acceptable binding agent by weight of the core,
(iii) from 0% to 5% of the optional at least one pharmaceutically acceptable excipient by weight of the core, and
(iv) up to 5% of the enzyme-friendly organic solvent by weight of the core.
101. The pharmaceutical composition of claim 100 , wherein the at least one pharmaceutically acceptable binding agent is polyethylene glycol 4000.